An Open-Label Study of AMG 386 in Combination With Either Paclitaxel and Trastuzumab or Capecitabine and Lapatinib in Subjects With HER2-Positive Locally Recurrent or Metastatic Breast Cancer

Trial Profile

An Open-Label Study of AMG 386 in Combination With Either Paclitaxel and Trastuzumab or Capecitabine and Lapatinib in Subjects With HER2-Positive Locally Recurrent or Metastatic Breast Cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Nov 2015

At a glance

  • Drugs Trebananib (Primary) ; Capecitabine; Lapatinib; Paclitaxel; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Sponsors Amgen
  • Most Recent Events

    • 30 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Oct 2015 Planned End Date changed from 1 Feb 2016 to 1 Nov 2015 as reported by ClinicalTrials.gov
    • 10 Aug 2015 Planned End Date changed from 1 Oct 2015 to 1 Feb 2016 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top